DK2668959T3 - Immunogene forbindelser omfattende HIV gp41-peptid koblet til CRM197-bærerprotein - Google Patents

Immunogene forbindelser omfattende HIV gp41-peptid koblet til CRM197-bærerprotein Download PDF

Info

Publication number
DK2668959T3
DK2668959T3 DK12305602.0T DK12305602T DK2668959T3 DK 2668959 T3 DK2668959 T3 DK 2668959T3 DK 12305602 T DK12305602 T DK 12305602T DK 2668959 T3 DK2668959 T3 DK 2668959T3
Authority
DK
Denmark
Prior art keywords
peptide
hiv
immunogenic compound
formula
crm197
Prior art date
Application number
DK12305602.0T
Other languages
English (en)
Inventor
Joel Crouzet
Dominique Desfontaines
Tsong Fang Raphaël Ho
Original Assignee
Innavirvax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innavirvax filed Critical Innavirvax
Application granted granted Critical
Publication of DK2668959T3 publication Critical patent/DK2668959T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Claims (15)

1. Immunogen forbindelse, som omfatter et peptid valgt fra gruppen bestående af følgende formler (Via) og (VIb): NH2-(Al)m-SEQ ID NO 2-(A2 )n-COOH (Via), NH2- (A1U-SEQ ID NO 6- (A2) n-COOH (VIb), hvor: - m er et heltal med betydningen 0 eller 1, - n er et heltal med betydningen 0 eller 1, - Al er en aminosyrest, og - A2 er en aminosyrest, hvilket peptid med formlen (IVa) eller (VIb) er kovalent bundet til et bærerprotein bestående af et CRM197-protein.
2. Immunogen forbindelse ifølge krav 1, som er valgt fra gruppen bestående af SEQ ID NO 5 og SEQ ID NO 7.
3. Immunogen forbindelse ifølge et hvilket som helst af kravene 1 til 2, som er kovalent bundet til CRM197-proteinet via dens N-terminale aminosyrerest.
4. Immunogen forbindelse ifølge et hvilket som helst af kravene 1 til 3, som er kovalent bundet til CRM197-proteinet gennem en linkergruppe.
5. Immunogen forbindelse ifølge krav 4, hvor linkergruppen er reaktionsproduktet af et linkermiddel, som har to reaktive grupper, med både CRM197 og et peptid med formlen (Via) eller (VIb) .
6. Immunogen forbindelse ifølge krav 5, hvor linkergruppen består af succimidyl-4-[p-maleimidophenyl]butyrat (SMPB) og sulfo-SMPB.
7. Sammensætning, som omfatter en immunogen forbindelse ifølge et hvilket som helst af kravene 1 til 6 i kombination med et eller flere immunoadjuvante stoffer.
8. Sammensætning ifølge krav 7, som er tilpasset til at danne en brugsklar vaccinesammensætning, der omfatter en mængde af den immunogene forbindelse i intervallet fra 0,01 yg til 200 yg pr. doseringsenhed udtrykt som ækvivalent antigent peptid, fortrinsvis fra 0,05 yg til 50 yg per doseringsenhed, og mest fortrinsvis fra 0,1 yg til 20 yg pr. doseringsenhed.
9. Sammensætning ifølge et hvilket som helst af kravene 7 og 8, hvor det immunoadjuvante stof består af aluminiumhydroxid (Al (OH)3) .
10. Sammensætning ifølge krav 9, som er tilpasset til at danne en brugsklar vaccinesammensætning, der omfatter en slutkoncentration af aluminiumhydroxid i intervallet fra 0,1 mg/ml til 5 mg/ml, fortrinsvis fra 0,05 mg/ml til 2 mg/ml, og mest fortrinsvis på 1 mg/ml, udtrykt som koncentration af Al3+-ioner.
11. Sammensætning ifølge et hvilket som helst af kravene 8 til 10, som er tilpasset til at danne en brugsklar vaccinesammensætning, der omfatter en slutkoncentration på 0,1 mM til 50 mM natriumphosphat, fortrinsvis 0,5 mM til 15 mM natriumphosphat, og mest fortrinsvis på 1 mM natriumphosphat.
12. Sammensætning ifølge et hvilket som helst af kravene 8 til 11, som er på en flydende form eller på en fast form, herunder på en lyofiliseret form.
13. Vaccinesammensætning, som omfatter en immunogen forbindelse ifølge et hvilket som helst af kravene 1 til 6 eller en sammensætning ifølge et hvilket som helst af kravene 7 til 12 med en eller flere farmaceutisk acceptable bærere.
14. Forbindelse ifølge et hvilket som helst af kravene 1 til 6 eller sammensætning ifølge et hvilket som helst af kravene 7 til 12 eller vaccinesammensætning ifølge krav 13 til anvendelse som lægemiddel.
15. Immunogen forbindelse ifølge et hvilket som helst af kravene 1 til 6 eller sammensætning ifølge et hvilket som helst af kravene 7 til 12 eller vaccinesammensætning ifølge krav 13 til anvendelse til forebyggelse og/eller behandling af en sygdom, der skyldes infektion af et individ med en HIV-virus.
DK12305602.0T 2012-05-31 2012-05-31 Immunogene forbindelser omfattende HIV gp41-peptid koblet til CRM197-bærerprotein DK2668959T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12305602.0A EP2668959B1 (en) 2012-05-31 2012-05-31 Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein

Publications (1)

Publication Number Publication Date
DK2668959T3 true DK2668959T3 (da) 2015-01-26

Family

ID=48793339

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12305602.0T DK2668959T3 (da) 2012-05-31 2012-05-31 Immunogene forbindelser omfattende HIV gp41-peptid koblet til CRM197-bærerprotein

Country Status (21)

Country Link
US (1) US9511136B2 (da)
EP (2) EP2668959B1 (da)
JP (1) JP6352251B2 (da)
KR (1) KR102077876B1 (da)
CN (1) CN104507496B (da)
AU (1) AU2013269120B2 (da)
BR (1) BR112014029861B1 (da)
CA (1) CA2875162C (da)
DK (1) DK2668959T3 (da)
EA (1) EA027803B1 (da)
ES (2) ES2528109T3 (da)
HR (1) HRP20150058T1 (da)
IN (1) IN2014DN10128A (da)
MX (1) MX360206B (da)
PL (1) PL2668959T3 (da)
PT (1) PT2668959E (da)
RS (1) RS53769B1 (da)
SI (1) SI2668959T1 (da)
UA (1) UA118542C2 (da)
WO (1) WO2013179262A1 (da)
ZA (1) ZA201409023B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335119A1 (en) * 2004-02-06 2014-11-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
RU2726411C2 (ru) * 2015-04-17 2020-07-14 Биолайф Сайенс Клд Лимитед Вакцинная композиция и ее применения
WO2016184973A1 (en) * 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
JP4696079B2 (ja) * 2003-12-17 2011-06-08 ヤンセン アルツハイマー イミュノセラピー Ａβ免疫原性ペプチド担体結合物およびそれの製造方法
US20110305749A1 (en) * 2008-08-28 2011-12-15 Mogens Ryttergaard Duch HIV-1 Envelope Polypeptides for HIV Vaccine
US7965010B2 (en) * 2008-09-03 2011-06-21 Bose Corporation Linear motor with patterned magnet arrays
WO2010040853A1 (en) * 2008-10-10 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method

Also Published As

Publication number Publication date
KR20150032266A (ko) 2015-03-25
CA2875162A1 (en) 2013-12-05
CN104507496B (zh) 2018-08-03
ZA201409023B (en) 2016-08-31
BR112014029861B1 (pt) 2022-05-24
RS53769B1 (sr) 2015-06-30
IN2014DN10128A (da) 2015-08-21
KR102077876B1 (ko) 2020-02-14
US20150147348A1 (en) 2015-05-28
UA118542C2 (uk) 2019-02-11
EA201491969A1 (ru) 2015-04-30
AU2013269120B2 (en) 2017-04-20
EP2854846A1 (en) 2015-04-08
AU2013269120A1 (en) 2014-12-18
CN104507496A (zh) 2015-04-08
EA027803B1 (ru) 2017-09-29
PT2668959E (pt) 2015-02-05
MX2014014526A (es) 2015-06-02
BR112014029861A2 (pt) 2017-07-25
ES2701084T3 (es) 2019-02-20
WO2013179262A1 (en) 2013-12-05
JP6352251B2 (ja) 2018-07-04
US9511136B2 (en) 2016-12-06
ES2528109T3 (es) 2015-02-04
HRP20150058T1 (hr) 2015-04-10
CA2875162C (en) 2021-09-14
JP2015519359A (ja) 2015-07-09
SI2668959T1 (sl) 2015-03-31
EP2854846B1 (en) 2018-09-12
EP2668959A1 (en) 2013-12-04
EP2668959B1 (en) 2014-11-05
PL2668959T3 (pl) 2015-04-30
MX360206B (es) 2018-10-24

Similar Documents

Publication Publication Date Title
AU2013269120B2 (en) Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
EP2758038B1 (en) Novel influenza hemagglutinin protein-based vaccines
SK362692A3 (en) Expression of specific immunogens by using of virus antigene
JP2012500829A (ja) Ｃｂｄ１エピトープにおけるオーバーラップする中和決定基に対応する合成ペプチドによって広域中和抗体が誘導される
WO2010045613A1 (en) Immunoenhancer-linked oligomeric hiv vaccines
JP2010506926A (ja) Ｉｉ−Ｋｅｙ増強ワクチンの効力
WO2016184962A1 (en) Treatment of hiv-infected individuals
WO2016184973A1 (en) Treatment of hiv-infected individuals
WO2012050893A2 (en) Immunogenic polypeptides having an immunogenic scaffold protein and a loop peptide, presenting a 3074- or 2219/2557- monoclonal antibody-targeted epitope, which is present in the hiv gp120 protein
WO2022242432A1 (en) Peptide vaccine for virus infection
US7943140B2 (en) Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1
AU731367B2 (en) HIV p-17 peptide fragment, compositions containing and methods for producing and using same
JP2009536653A (ja) Ｈｉｖ−１免疫原性組成物
JP2003533542A (ja) Ｔ細胞結合リガンド、それを含むペプチド構築物およびそれらの免疫障害を処置するための使用
WO2012140424A2 (en) Composition